Background:Takayasu arteritis-induced renal arteritis (TARA), commonly seen in Takayasu arteritis (TA), has become one of the main causes of poor prognosis and early mortality in patients with TA. TARA progressing int...Background:Takayasu arteritis-induced renal arteritis (TARA), commonly seen in Takayasu arteritis (TA), has become one of the main causes of poor prognosis and early mortality in patients with TA. TARA progressing into Takayasu arteritis-induced renal artery stenosis (TARAS), could lead to severe complications including malignant hypertension, cardiac-cerebral vascular disease, and ischemic nephropathy. Since there existed no guidelines on treatments, this study aimed to review the comprehensive treatments for TARA.Methods:We searched systematically in databases including PubMed, Ovid-Medline, EMBASE, Web of Science, China National Knowledge Infrastructure, Wanfang, and SinoMed, from inception to May 2018. Literature selection, data extraction, and statistical analysis were performed.Results:Eighty-two literatures were recruited focusing on medical treatments ( n = 34) and surgical treatments ( n = 48). We found that combined medical treatments of glucocorticoids and conventional synthetic disease-modifying anti-rheumatic drugs could reach high rates of remission in patients with TARA, and biological disease-modifying anti-rheumatic drugs were preferred for refractory patients. After remission induction, surgical treatment could help reconstruct renal artery and recover renal function partly. Percutaneous transluminal angioplasty was the first choice for patients with TARAS, while open surgery showed a good longterm survival. Conclusions:Patients with TARA should benefit both from medical treatments and from surgical treatments comprehensively and sequentially. Multidisciplinary team coordination is recommended especially in patients with severe complications.展开更多
BACKGROUND Takayasu arteritis is a rare but intractable chronic disease in young female patients. Percutaneous transluminal angioplasty of the involved renal arteries has been reported;however, few studies have report...BACKGROUND Takayasu arteritis is a rare but intractable chronic disease in young female patients. Percutaneous transluminal angioplasty of the involved renal arteries has been reported;however, few studies have reported the use of drug coated balloon angioplasty in the treatment of Takayasu arteritis. We aimed to demonstrate five young female patients who presented with a history of hypertension due to Takayasu arteritis. CASE SUMMARY From April 2017 to October 2018, five female patients were diagnosed with hypertension due to Takayasu arteritis by computed tomography angiography (CTA) and laboratory tests. Four patients had a complaint of headache with or without dizziness, and one patient showed no symptom. There was no significant family or past history of hypertension or kidney disease, and the physical examinations were almost normal on admission. We performed a treatment by drug coated balloon angioplasty. Blood pressure decreased dramatically in all patients after balloon angioplasty, and the patency of treated renal artery was demonstrated with CTA over 5 months after the angioplasty procedure. CONCLUSION Drug coated balloon angioplasty is safe and effective for renal artery stenosis due to Takayasu arteritis. A prospective study with a larger sample size is necessary to further demonstrate the effectiveness of the treatment.展开更多
Takayasu arteritis （TA） is a nonspecific granulomatous inflammatory arteriopathy of unknown cause that results in occlusive obliteration or less commonly aneurysm degeneration of large and medium-sized elastic arter...Takayasu arteritis （TA） is a nonspecific granulomatous inflammatory arteriopathy of unknown cause that results in occlusive obliteration or less commonly aneurysm degeneration of large and medium-sized elastic arteries. Most descriptions of this disease have emphasized the ＂pulseless＂ syndrome, however, less attention has been paid to involvement of other segments of the aorta, renal arteries, and in particular the visceral arteries. We reported a case of type Ⅱ TA, in which both the visceral and the bilateral renal arteries were involved.展开更多
Takayasu arteritis （TA） commonly occurs in woman younger than 50 years old and can manifest as isolated, atypical and/or catas- trophic disease. The disease can implicate in any or all of the major organs I As a chr...Takayasu arteritis （TA） commonly occurs in woman younger than 50 years old and can manifest as isolated, atypical and/or catas- trophic disease. The disease can implicate in any or all of the major organs I As a chronic relapsing and remitting disorder, the overall 10-year survival rate is approximately 90%; however, this rate is reduced in the presence of major complications. The overall mortality rate of TA depends on the severity of the le- sions and involved organs.展开更多
目的:研究采用单条大隐静脉行腹主动脉-双侧肾动脉旁路术治疗大动脉炎性双侧肾动脉狭窄的疗效。方法:回顾性分析采用该术式治疗的11例大动脉炎性双侧肾动脉狭窄的连续临床资料。结果:所有病人术前均表现为难控性高血压,1例需依赖血透生...目的:研究采用单条大隐静脉行腹主动脉-双侧肾动脉旁路术治疗大动脉炎性双侧肾动脉狭窄的疗效。方法:回顾性分析采用该术式治疗的11例大动脉炎性双侧肾动脉狭窄的连续临床资料。结果:所有病人术前均表现为难控性高血压,1例需依赖血透生存。11例均顺利完成手术,22条肾动脉即刻复通,无围手术期死亡。平均随访时间为45个月。末次随访时平均血压由术前的195/109 mm Hg降至132/83 mm Hg(P<0.05);平均降压药物用量由术前的2.8 DDD降为0.7 DDD(P<0.05);平均估算肾小球滤过率由术前的68 mL/min增至89 mL/min(P<0.05);术前血透依赖者不再需要进行血透。未发现移植物闭塞或>50%的再狭窄。结论:该术式是治疗双侧大动脉炎性肾动脉狭窄之安全、有效的方法;可有效降压和改善肾功能;中远期通畅率高。展开更多
Takayasu＇s Arteritis is a chronic non-specific inflammatory vascular disease involving the aorta and its major branches. Takayasu＇s arteritis is one of important reason for renal artery stenosis（RAS） which may res...Takayasu＇s Arteritis is a chronic non-specific inflammatory vascular disease involving the aorta and its major branches. Takayasu＇s arteritis is one of important reason for renal artery stenosis（RAS） which may result in severe hypertension. Angioplasty, preferably with stenting, is recommended in RAS secondary to atherosclerosis. However, the safety and efficacy of stent implantation is still unclear in RAS caused by Takayasu＇s arteritis. In order to raise the awareness for the importance of Takayasu＇s arteritis in renal artery disease and further to discuss the endovascular revascularization strategies, we are going to present a case report regarding RAS resulted by Takayasu＇s arteritis and provide a timely summary and update on current understanding.展开更多
基金This work was supported by a grant from the National Natural Science Foundation of China(No.81771730)。
文摘Background:Takayasu arteritis-induced renal arteritis (TARA), commonly seen in Takayasu arteritis (TA), has become one of the main causes of poor prognosis and early mortality in patients with TA. TARA progressing into Takayasu arteritis-induced renal artery stenosis (TARAS), could lead to severe complications including malignant hypertension, cardiac-cerebral vascular disease, and ischemic nephropathy. Since there existed no guidelines on treatments, this study aimed to review the comprehensive treatments for TARA.Methods:We searched systematically in databases including PubMed, Ovid-Medline, EMBASE, Web of Science, China National Knowledge Infrastructure, Wanfang, and SinoMed, from inception to May 2018. Literature selection, data extraction, and statistical analysis were performed.Results:Eighty-two literatures were recruited focusing on medical treatments ( n = 34) and surgical treatments ( n = 48). We found that combined medical treatments of glucocorticoids and conventional synthetic disease-modifying anti-rheumatic drugs could reach high rates of remission in patients with TARA, and biological disease-modifying anti-rheumatic drugs were preferred for refractory patients. After remission induction, surgical treatment could help reconstruct renal artery and recover renal function partly. Percutaneous transluminal angioplasty was the first choice for patients with TARAS, while open surgery showed a good longterm survival. Conclusions:Patients with TARA should benefit both from medical treatments and from surgical treatments comprehensively and sequentially. Multidisciplinary team coordination is recommended especially in patients with severe complications.
基金Supported by the National Natural Science Foundation of China,No.81501569
文摘BACKGROUND Takayasu arteritis is a rare but intractable chronic disease in young female patients. Percutaneous transluminal angioplasty of the involved renal arteries has been reported;however, few studies have reported the use of drug coated balloon angioplasty in the treatment of Takayasu arteritis. We aimed to demonstrate five young female patients who presented with a history of hypertension due to Takayasu arteritis. CASE SUMMARY From April 2017 to October 2018, five female patients were diagnosed with hypertension due to Takayasu arteritis by computed tomography angiography (CTA) and laboratory tests. Four patients had a complaint of headache with or without dizziness, and one patient showed no symptom. There was no significant family or past history of hypertension or kidney disease, and the physical examinations were almost normal on admission. We performed a treatment by drug coated balloon angioplasty. Blood pressure decreased dramatically in all patients after balloon angioplasty, and the patency of treated renal artery was demonstrated with CTA over 5 months after the angioplasty procedure. CONCLUSION Drug coated balloon angioplasty is safe and effective for renal artery stenosis due to Takayasu arteritis. A prospective study with a larger sample size is necessary to further demonstrate the effectiveness of the treatment.
文摘Takayasu arteritis （TA） is a nonspecific granulomatous inflammatory arteriopathy of unknown cause that results in occlusive obliteration or less commonly aneurysm degeneration of large and medium-sized elastic arteries. Most descriptions of this disease have emphasized the ＂pulseless＂ syndrome, however, less attention has been paid to involvement of other segments of the aorta, renal arteries, and in particular the visceral arteries. We reported a case of type Ⅱ TA, in which both the visceral and the bilateral renal arteries were involved.
文摘Takayasu arteritis （TA） commonly occurs in woman younger than 50 years old and can manifest as isolated, atypical and/or catas- trophic disease. The disease can implicate in any or all of the major organs I As a chronic relapsing and remitting disorder, the overall 10-year survival rate is approximately 90%; however, this rate is reduced in the presence of major complications. The overall mortality rate of TA depends on the severity of the le- sions and involved organs.
文摘目的:研究采用单条大隐静脉行腹主动脉-双侧肾动脉旁路术治疗大动脉炎性双侧肾动脉狭窄的疗效。方法:回顾性分析采用该术式治疗的11例大动脉炎性双侧肾动脉狭窄的连续临床资料。结果:所有病人术前均表现为难控性高血压,1例需依赖血透生存。11例均顺利完成手术,22条肾动脉即刻复通,无围手术期死亡。平均随访时间为45个月。末次随访时平均血压由术前的195/109 mm Hg降至132/83 mm Hg(P<0.05);平均降压药物用量由术前的2.8 DDD降为0.7 DDD(P<0.05);平均估算肾小球滤过率由术前的68 mL/min增至89 mL/min(P<0.05);术前血透依赖者不再需要进行血透。未发现移植物闭塞或>50%的再狭窄。结论:该术式是治疗双侧大动脉炎性肾动脉狭窄之安全、有效的方法;可有效降压和改善肾功能;中远期通畅率高。
文摘Takayasu＇s Arteritis is a chronic non-specific inflammatory vascular disease involving the aorta and its major branches. Takayasu＇s arteritis is one of important reason for renal artery stenosis（RAS） which may result in severe hypertension. Angioplasty, preferably with stenting, is recommended in RAS secondary to atherosclerosis. However, the safety and efficacy of stent implantation is still unclear in RAS caused by Takayasu＇s arteritis. In order to raise the awareness for the importance of Takayasu＇s arteritis in renal artery disease and further to discuss the endovascular revascularization strategies, we are going to present a case report regarding RAS resulted by Takayasu＇s arteritis and provide a timely summary and update on current understanding.
